Bridgette Kram1, Kylie M Weigel2, Michelle Kuhrt1, Daniel L Gilstrap3. 1. Clinical Pharmacist, Department of Pharmacy, Duke University Hospital, Durham, North Carolina. 2. Clinical Pharmacist, Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts. 3. Division of Pulmonology, Allergy, and Critical Care Medicine, Duke University Hospital, Durham, North Carolina.
Abstract
OBJECTIVE: To evaluate the proportion of patients receiving a hospital discharge prescription for a scheduled enteral opioid following initiation as a weaning strategy from a continuous opioid infusion in the Intensive Care Unit (ICU). DESIGN: Retrospective, observational study. SETTING: Five adult ICUs at a large, quaternary care academic medical center. PATIENTS: Endotracheally intubated, opioid-naive adults receiving a continuous opioid infusion with a concomitant scheduled enteral opioid initiated. Exclusion criteria were receipt of fewer than two enteral opioid doses, documentation of a long-acting opioid as a home medication, the indication for the enteral opioid was not a weaning strategy, death during hospital admission or discharge to hospice. INTERVENTIONS: None. MAIN OUTCOME MEASURES: The proportion of ICU and hospital survivors who received a discharge prescription for a scheduled enteral opioid, total duration of continuous opioid infusion, duration of continuous opioid infusion after initiation of an enteral opioid therapy, total duration of enteral therapy, ICU and hospital length of stay. RESULTS: Of 62 included patients, 19 patients (30.6 percent) received a new prescription for a scheduled enteral opioid at hospital discharge. The median duration of enteral opioid therapy was longer for patients who received a discharge prescription compared to those who did not (20.09 vs 8.89 days, p = 0.02), though the remaining endpoints were not different. CONCLUSIONS: Utilizing scheduled enteral opioids as a weaning strategy from continuous opioid infusions may place patients at risk of ICU-acquired physical dependence on opioids.
OBJECTIVE: To evaluate the proportion of patients receiving a hospital discharge prescription for a scheduled enteral opioid following initiation as a weaning strategy from a continuous opioid infusion in the Intensive Care Unit (ICU). DESIGN: Retrospective, observational study. SETTING: Five adult ICUs at a large, quaternary care academic medical center. PATIENTS: Endotracheally intubated, opioid-naive adults receiving a continuous opioid infusion with a concomitant scheduled enteral opioid initiated. Exclusion criteria were receipt of fewer than two enteral opioid doses, documentation of a long-acting opioid as a home medication, the indication for the enteral opioid was not a weaning strategy, death during hospital admission or discharge to hospice. INTERVENTIONS: None. MAIN OUTCOME MEASURES: The proportion of ICU and hospital survivors who received a discharge prescription for a scheduled enteral opioid, total duration of continuous opioid infusion, duration of continuous opioid infusion after initiation of an enteral opioid therapy, total duration of enteral therapy, ICU and hospital length of stay. RESULTS: Of 62 included patients, 19 patients (30.6 percent) received a new prescription for a scheduled enteral opioid at hospital discharge. The median duration of enteral opioid therapy was longer for patients who received a discharge prescription compared to those who did not (20.09 vs 8.89 days, p = 0.02), though the remaining endpoints were not different. CONCLUSIONS: Utilizing scheduled enteral opioids as a weaning strategy from continuous opioid infusions may place patients at risk of ICU-acquired physical dependence on opioids.
Authors: Luis E Tollinche; Kenneth P Seier; Gloria Yang; Kay See Tan; Yekaterina D Tayban; Stephen M Pastores; Cindy B Yeoh; Kunal Karamchandani Journal: J Crit Care Date: 2021-11-29 Impact factor: 4.298
Authors: Barbara Sneyers; Marc-Alexandre Duceppe; Anne Julie Frenette; Lisa D Burry; Philippe Rico; Annie Lavoie; Céline Gélinas; Sangeeta Mehta; Maryse Dagenais; David R Williamson; Marc M Perreault Journal: Drugs Date: 2020-08 Impact factor: 9.546
Authors: Chelsea Wampole; Ariel McKenna; Richard R Riker; Teresa L May; David B Seder; Dawn Abram; Gilles L Fraser; David J Gagnon Journal: Crit Care Explor Date: 2022-07-26